{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:24:11Z","timestamp":1791404651087,"version":"4.3.3"},"reference-count":88,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The treatment of human immunodeficiency virus (HIV-1) has evolved since the establishment of combination antiretroviral therapy (ART) in the 1990s, providing HIV-infected individuals with approaches that suppress viral replication, prevent acquired immunodeficiency syndrome (AIDS) throughout their lifetime with continuous therapy, and halt HIV transmission. However, despite the success of these regimens, the global HIV epidemic persists, prompting a comprehensive exploration of potential strategies for an HIV cure. Here, we offer a consolidated overview of cell-based therapies for HIV-1, focusing on CAR-T cell approaches, gene editing, and immune modulation. Persistent challenges, including CAR-T cell susceptibility to HIV infection, stability, and viral reservoir control, underscore the need for continued research. This review synthesizes current knowledge, highlighting the potential of cellular therapies to address persistent challenges in the pursuit of an HIV cure.<\/jats:p>","DOI":"10.3390\/cells13010064","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T09:56:27Z","timestamp":1703757387000},"page":"64","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Advancements in Cell-Based Therapies for HIV Cure"],"prefix":"10.3390","volume":"13","author":[{"given":"Yusuke","family":"Matsui","sequence":"first","affiliation":[{"name":"Gladstone Institute of Virology, Gladstone Institutes, 1650 Owens St., San Francisco, CA 941578, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-1300","authenticated-orcid":false,"given":"Yasuo","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake 470-1192, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: Single versus multiple tablet regimen comparison among US medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.2018.21167","article-title":"HIV Viral Load and Transmissibility of HIV Infection","volume":"321","author":"Eisinger","year":"2019","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: Results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Hughes","year":"2022","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","unstructured":"UNAIDS (2022). Global HIV & AIDS Statistics\u2014Fact Sheet, UNAIDS."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1038\/s41467-019-12141-5","article-title":"Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery","volume":"10","author":"Benhabbour","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1038\/s41467-018-06490-w","article-title":"Ultra-long-acting removable drug delivery system for HIV treatment and prevention","volume":"9","author":"Kovarova","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41586-019-1841-8","article-title":"Why and where an HIV cure is needed and how it might be achieved","volume":"576","author":"McCune","year":"2019","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1084\/jem.20170193","article-title":"Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics","volume":"214","author":"Hosmane","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","article-title":"Targeting the Latent Reservoir for HIV-1","volume":"48","author":"Sengupta","year":"2018","journal-title":"Immunity"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-020-1951-3","article-title":"Systemic HIV and SIV latency reversal via non-canonical NF-\u03baB signalling in vivo","volume":"578","author":"Nixon","year":"2020","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2017.09.080","article-title":"In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a \u201cBlock-and-Lock\u201d Strategy for HIV-1 Treatment","volume":"21","author":"Kessing","year":"2017","journal-title":"Cell Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1038\/s41467-020-19821-7","article-title":"CRISPR based editing of SIV proviral DNA in ART treated non-human primates","volume":"11","author":"Mancuso","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_18","unstructured":"U.S. National Library of Medicine (2023, November 29). ClinicalTrials.Gov\u2014Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05144386."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41586-020-2651-8","article-title":"Distinct viral reservoirs in individuals with spontaneous control of HIV-1","volume":"585","author":"Jiang","year":"2020","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/L21-0297","article-title":"A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation","volume":"175","author":"Turk","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e122795","DOI":"10.1172\/jci.insight.122795","article-title":"Long-term remission despite clonal expansion of replication-competent HIV-1 isolates","volume":"3","author":"Veenhuis","year":"2018","journal-title":"JCI Insight"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.1128\/JVI.00800-08","article-title":"Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor","volume":"82","author":"Bailey","year":"2008","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-023-01479-5","article-title":"BCMA-targeted CAR-T cell therapies in relapsed and\/or refractory multiple myeloma: Latest updates from 2023 ASCO Annual Meeting","volume":"16","author":"Wu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: Next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/d41573-023-00140-7","article-title":"The next-generation CAR-T therapy landscape","volume":"22","author":"Verma","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mehrabadi, A.Z., Ranjbar, R., Farzanehpour, M., Shahriary, A., Dorostkar, R., Hamidinejad, M.A., and Ghaleh, H.E.G. (2022). Therapeutic potential of CAR T cell in malignancies: A scoping review. Biomed. Pharmacother., 146.","DOI":"10.1016\/j.biopha.2021.112512"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcyt.2015.10.014","article-title":"T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G\u2013opsonized target cells","volume":"18","author":"Caratelli","year":"2016","journal-title":"Cytotherapy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","article-title":"T Lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing","volume":"74","author":"Kudo","year":"2014","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eaba7308","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00262-014-1568-1","article-title":"Engineered T cells for cancer therapy","volume":"63","author":"June","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_41","first-page":"467","article-title":"Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e150211","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody\u2013derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/d41591-023-00042-6","article-title":"First two patients receive CAR T cell therapy for HIV","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.cell.2019.10.002","article-title":"Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform","volume":"179","author":"Herzig","year":"2019","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: A phase 1 dose-escalation clinical trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1213256","article-title":"A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield","volume":"334","author":"Pejchal","year":"2011","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.immuni.2017.03.017","article-title":"A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic \u03b2-Hairpin Structure","volume":"46","author":"Lee","year":"2017","journal-title":"Immunity"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e02249-17","DOI":"10.1128\/JVI.02249-17","article-title":"Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions","volume":"92","author":"Rujas","year":"2018","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","article-title":"Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells","volume":"25","author":"Hale","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/381661a0","article-title":"Identification of a major co-receptor for primary isolates of HIV-1","volume":"381","author":"Deng","year":"1996","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eaav5685","DOI":"10.1126\/scitranslmed.aav5685","article-title":"Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model","volume":"11","author":"Bardhi","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e161698","DOI":"10.1172\/jci.insight.161698","article-title":"In vivo killing of primary HIV-infected cells by peripheral-injected early memory\u2013enriched anti-HIV duoCAR T cells","volume":"7","author":"Ray","year":"2022","journal-title":"JCI insight"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17121","DOI":"10.1073\/pnas.0805297105","article-title":"Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers","volume":"105","author":"Chen","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Landgraf, K.E., Williams, S.R., Steiger, D., Gebhart, D., Lok, S., Martin, D.W., Roybal, K.T., and Kim, K.C. (2020). convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting. Commun. Biol., 3.","DOI":"10.1038\/s42003-020-1021-2"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Sutherland, A.R., Owens, M.N., and Geyer, C.R. (2020). Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197222"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9712","DOI":"10.1128\/JVI.00852-16","article-title":"Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy","volume":"90","author":"Liu","year":"2016","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Pampusch, M.S., Abdelaal, H.M., Cartwright, E.K., Molden, J.S., Davey, B.C., Sauve, J.D., Sevcik, E.N., Rendahl, A.K., Rakasz, E.G., and Connick, E. (2022). CAR\/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection. PLOS Pathog., 18.","DOI":"10.1371\/journal.ppat.1009831"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e167417","DOI":"10.1172\/JCI167417","article-title":"Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy","volume":"133","author":"Tang","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.1038\/s41598-017-12758-w","article-title":"HIV-infected macrophages and microglia that survive acute infection become viral reservoirs by a mechanism involving Bim","volume":"7","author":"Castellano","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1084\/jem.20070064","article-title":"An antigen-specific pathway for CD8 T cells across the blood-brain barrier","volume":"204","author":"Galea","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3389\/fonc.2020.01582","article-title":"CAR-T cell therapy for pediatric brain tumors","volume":"10","author":"Patterson","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"835994","DOI":"10.3389\/fimmu.2022.835994","article-title":"CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair","volume":"13","author":"Jasinska","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1073\/pnas.94.5.1925","article-title":"The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes","volume":"94","author":"Bleul","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1515\/med-2018-0062","article-title":"The CCR5-Delta32 Genetic Polymorphism and HIV-1 Infection Susceptibility: A Meta-analysis","volume":"13","author":"Ni","year":"2018","journal-title":"Open Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"Nowak","year":"2009","journal-title":"New Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","article-title":"In-depth virological and immunological characterization of HIV-1 cure after CCR5\u039432\/\u039432 allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Jensen","year":"2023","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","article-title":"HIV-1 remission and possible cure in a woman after haplo-cord blood transplant","volume":"186","author":"Hsu","year":"2023","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Yukl, S.A., Boritz, E., Busch, M., Bentsen, C., Chun, T.-W., Douek, D., Eisele, E., Haase, A., Ho, Y.-C., and H\u00fctter, G. (2013). Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003347"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","article-title":"Prevention, treatment and cure of HIV infection","volume":"21","author":"Landovitz","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e144486","DOI":"10.1172\/JCI144486","article-title":"CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia","volume":"381","author":"Xu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ymthe.2020.05.012","article-title":"HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo","volume":"28","author":"Maldini","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.ymthe.2020.06.008","article-title":"Replacing cART with CAR-T Cells: Using Immunotherapy to Cure HIV","volume":"28","author":"Beck","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Liu, C., Ma, X., Liu, B., Chen, C., and Zhang, H. (2015). HIV-1 functional cure: Will the dream come true?. BMC Med., 13.","DOI":"10.1186\/s12916-015-0517-y"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"eaay9355","DOI":"10.1126\/scitranslmed.aay9355","article-title":"Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1","volume":"12","author":"Eberhard","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/PPO.0000000000000155","article-title":"Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity","volume":"21","author":"Maus","year":"2015","journal-title":"Cancer J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1038\/s41598-019-41869-9","article-title":"The clinical features and prognosis of 100 AIDS-related lymphoma cases","volume":"9","author":"Wu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_86","unstructured":"U.S. National Library of Medicine (2023, November 29). ClinicalTrials.Gov\u2014Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05077527."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: A phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41422-022-00745-4","article-title":"Off-the-shelf CAR T cells to treat cancer","volume":"32","author":"Castelli","year":"2022","journal-title":"Cell Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/1\/64\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:43:18Z","timestamp":1760132598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/1\/64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cells13010064"],"URL":"https:\/\/doi.org\/10.3390\/cells13010064","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}